ABSTRACT. The surface glycoprotein G is considered as the major neutralizing and protective antigen of bovine ephemeral fever virus (BEFV). Comparison of the deduced amino acid sequence of G protein of BEFV isolates during the period 1984-2004 outbreaks in Taiwan showed amino acid substitutions in the neutralizing epitopes. All the isolates differ markedly in the neutralizing epitope at the same amino acid positions compared to the currently available killed vaccine strain (Tn73). Tn88128 strain isolated in 1999 showed the maximum variability of 12 amino acids, 5 amino acid in the neutralization epitope and 7 apart from, respectively. Combinations of both Tn88128 (1999) and commercially available vaccine strain (Tn73) were developed and its safety was evaluated in mice, guinea pigs, calves, and pregnant cows. None of the animals showed any adverse effect or clinical signs. Calves were immunized with commercial vaccine (Tn73) and, combined vaccine (Tn73 and Tn88128), respectively, with adjuvants such as Al-gel and water-in-oil-in-water (w/o/ w) oil and PBS alone and challenged with Tn88128 strains. Except PBS administered animals, all the vaccinated animals showed protective immune response. However, animals immunized with combined vaccine plus w/o/w adjuvant elicited stronger neutralization antibodies and long lasting immunity compared to other vaccines. KEY WORDS: bovine ephemeral fever virus, genotyping, vaccine.
Bovine ephemeral fever virus (BEFV) is an arthropod borne rhabdovirus which has been classified as the genus Ephemerovirus of the rhabdoviridae family [15] , which causes an acute febrile disease with nasal discharge, lameness, depression and other inflammatory reactions [16, 18, 22, 26] . BEFV is a bullet-or cone-shaped virion which consists of a negative, single-stranded RNA genome with lipid envelope and five structural proteins [8, 22] . The envelope glycoprotein G contains type-specific and neutralizing antigenic sites [7, 11, 23, 24] . More recently, evidence is provided demonstrating that BEFV induces apotosis in several cell lines [4] .
Several outbreaks of BEFV infections in cattle have been reported in Taiwan from 1967 to 2004 [4-6, 10, 12, 13, 25] . Infection spreads out rapidly causing heavy morbidity, which results in culling of cattle. Currently available killed vaccine (Tn73 strain) does not provide cross protection against different isolates of BEFV in the cattle [24] . The failure of the current vaccine may be due to mutation of the protective antigen, especially on the surface glycoprotein, and/or an ineffective adjuvant system.
In this study, we analyzed the glycoprotein G-encoding gene of 17 field isolates isolated from 1984 to 2004 [10] and compared to commercially available vaccine Tn73 strain. A new double oil adjuvant bivalent vaccine that contained both the recent strain Tn88128 (1999 isolate) which showed maximum variation in the G protein and the commercially available vaccine (Tn73) strain was developed and its immunoprotective potential was evaluated in cattle. [10] . These strains were passaged in Baby Hamster Kidney (BHK-21) cells. The virus was purified by plaque purification three times in BHK-21 cells and further purified by sucrose-gradient centrifugation. The identity of the virus was confirmed by reverse-transcription and polymerase chain reaction (RT-PCR), indirect-fluorescent assay and negative stain using transmission electron microscope. The pathogenicity of the virus was confirmed by animal-inoculation experiments. Strain Tn88128 isolated in the 1999 outbreak of BEF was used to develop a new version of killed vaccine. The original vaccine strain, Tn73 was also available at our disease control center. 60°C for 5 min to denature RNA, 42°C for 45 min to synthesis cDNA, then 40 cycles of PCR amplification (94°C for 1 min, 55°C for 1 min, and 72°C for 1 min). The amplification was terminated with a final elongation step at 72°C for 10 min (Thermocycler, TaKaRa, Japan). The amplified products were analyzed by electrophoresis on a 1.5% agarose gel and visualized using an UV illuminator after ethidium bromide staining. Nucleotide sequencing and analysis: PCR products (1,872 bp) were purified individually with gel purification kit (Amersham Pharmacia Biotech, U.S.A.). The purified PCR products were sequenced directly with 4 pairs of primers (Table 1) [10, 25] derived from both ends and internal sequences using the DNA sequencing kit (Rhodamine Terminator Cycle Sequence Ready Reaction Kit, PE Applied Biosystems, U.S.A.). The obtained DNA sequences were aligned using Clustal W program (http://www.ebi.ac.uk/cgibin/clustalW).
MATERIALS AND METHODS

Viruses and cells:
Preparation of vaccine: The Tn88128 (5 BHK-21 passage) and Tn73 (7 BHK-21 passage) isolates of BEFV were inoculated individually onto BHK-21 monolayers and harvested at the height of cytopathic effect (CPE). The tissue culture infectious dose (TCID 50 ) of the virus was assessed and then inactivated by binary ethyleneimine (BEI; Sigma, U.S.A.) at a final concentration of 0.001 M [3] . The oil vaccine prepared with internal aqueous phase containing two inactivated antigens of Tn73 and Tn88128 from approximately 10 8.5 TCID 50 each: oil phase (KB ® CY 2 , Kaohsiung Biological Product Co., Taiwan): external aqueous phase ratios of 1:1:2. The w/o/w emulsion was prepared by twostep emulsification as previously described [14] . The same inactivated antigen (70% v/v) was mixed to the Al-gel adjuvant (30% v/v Aluminum hydroxide, Kaohsiung Biological Product Co., Taiwan).
Safety test: Ten (13-15 g) healthy BALB/CJ mice (NCKU Laboratory Animal Center, Taiwan) were intramuscularly (IM) administered with 0.25 ml of the vaccine. Two (250-300 g) healthy guinea pigs (NCKU Laboratory Animal Center, Taiwan) were given 2.0 ml of the vaccine via the IM route. Five 5-6-month-old healthy calves without antibodies against BEFV were given 3.0 ml of the vaccine via the IM route. All the vaccinated animals were observed daily for clinical signs for two weeks.
Ten Holstein, two to three months pregnant cows (Dou Shu Farm, Taiwan) were divided into two groups. Group 1 (8 cows) were given 3 ml of the vaccine via the IM route, and group 2 (2 cows) given with all gradients as in vaccine preparation, except not with the killed BEFV as the shamvaccinated controls. All the animals were observed till the day of parturition.
Potency test: Twenty 5-6-month-old calves obtained from local farm without BEFV antibody were divided into four groups (5 per group). Group A was given 3 ml of w/o/ w vaccine , group B was given 5 ml of Al-gel vaccine , group C was given 3 ml of commercial Al-gel vaccine (Biological & Chemical Co., Taiwan) and group D was the sham-vaccinated control. After four weeks, two calves from each group were relocated into the isolation facility and were given 5 ml of Tn88128 virus containing 10 5.5 TCID 50 / ml intravenously. The remaining calves were given one booster dose and bled every 4 weeks till the 6th month.
Serum neutralization test: Sera were incubated for 30 min at 56°C and diluted two-fold serially in 96-well microtiter plate, mixed with 200 TCID 50 of BEFV (100 µl) and incubated for 1 hr at 37°C in 5% CO 2 . After incubation, 100 µl of BHK-21 cell suspension containing 5 × 10 5 cells per ml was added and plates were incubated for 4 days at 37°C in 5% CO 2 . The antibody titers were expressed as the reciprocal of the highest dilution inhibiting CPE.
Cross-neutralization tests: Hyperimmune sera were prepared in New Zealand white rabbits. Each of the purified virus strains BEFV1984 (Tn73), BEFV1996, BEFV1999 
Determination of antigenic relatedness:
The antigenic relatedness of BEFV1984 (Tn73), BEFV1996, BEFV1999 (Tn88128) and BEFV2001 was expressed by R value, calculated and evaluated using the formula created by Archetti and Horsfall [2] , r 1 is the ratio of the heterologous titer obtained with virus 2 to the homologous titer obtained with virus 1; r 2 is the ratio of the heterologous titer obtained with virus 1 to the homologous titer obtained with virus 2. R is a geometric mean of ratio r 1 and r 2 , which is used to express the antigenic relatedness between two viruses when both antigens and antisera were used in cross-neutralization tests. A serotype difference is present if the R value falls between 0 and 5%; a subtype is present if the R value falls between 5.1 and 70%; and there is little or no difference present if the R value is greater than 70%.
RESULTS
Sequence analysis:
The deduced amino acid sequences of glycoprotein G of 17 were analyzed. Interestingly, all the field isolates showed similar variability in the neutralizing epitopes at the following positions (N 499 →S, E 194 →D, K 215 →E, A 220 →E, R 271 →Q) compared to Tn73 vaccine strain (BEFV1984). Apart from the changes in the neutralizing epitope, the isolates such as BEFV1996, BEFV1999, BEFV2001 (strains 1 to 11), and BEFV2004 (strains 1 to 3) also showed variability of 7, 7, 6 and 6 amino acids to that of Tn73, respectively ( Fig. 1) with that of the commercially available vaccine Tn73 strain. Table 2 presents R values obtained from all isolates using the cross-neutralization test. The R value of BEFV1984 (Tn73) among BEFV1996 was 16.1%, BEFV1999 (Tn88128) was 6.3%, BEFV2001 was 5.3%. All past and recent isolates belonged to a single serotype, but could be further classified into distinct subtypes. The R value of BEFV1999 (Tn88128) and BEFV2001 was 70.7% greater than 70% indicated little or no antigenic difference.
Cross-neutralization tests and R values:
Safety test: To examine whether the prepared oil-based vaccine consisting Tn73 and Tn88128 causes any adverse effects in animals, the combined vaccine was injected intramuscularly into mice, guinea pigs, and calves. Immunized animals showed no clinical signs such as fever, loss of appetite, depression, or local response at the injection sites for 2 weeks after post vaccination. In order to confirm its safety during pregnancy, the vaccine was intramuscularly injected into pregnant cows. No abortions or adverse reactions were observed and calves were delivered in the normal condition.
Challenge trial: All the vaccinated animals irrespective of the adjuvant or vaccine showed no clinical signs while the non-vaccinated animals exhibited clinical symptoms such as pyrexia, salivation and leukopenia (Table 3 ). The isolated viruses from the control group showed identical DNA sequence of the glycoprotein G gene with that of the challenge strain (Tn88128).
Antibody detection: Serum samples collected from all the cows at 0, 2, 4, 8, 10, 16 and 24 weeks after the vaccination were evaluated for the titer of neutralization antibodies to strain 1999 (Tn88128). Oil based vaccine stimulated the titer of neutralization antibodies to 1:256 after 8 weeks of vaccination and the antibody titer persisted till 6 months whereas commercial aluminum hydroxide vaccine, induced a titer of 1:32 after 8 weeks of vaccination and the titer lasted up to 2 months only (Fig. 2) .
DISCUSSION
Commercially available vaccine containing BEFV Tn73 (1984 isolate) fails to provide full cross protection against the current BEFV infection in the field [10] . This may be due to the variation of neutralizing epitopes on the surface glycoproteins. Comparison of amino acid sequences of glycoprotein G of the recent isolates with the vaccine strain BEFV1984 (Tn73) suggested that there are amino acid residue substitution at the neutralizing epitopes of glycoprotein [25] . All the isolates showed similar variability at the neutralizing epitopes compared to commercial vaccine strain (Tn73). Interestingly, out of all the isolates 1999 (Tn88128) isolate showed maximum amino acid substitutions (Fig. 1) .
All the field isolates exhibited the same amino acid substitution in the neutralization epitope on the surface glycoprotein. The Tn88128 strain also showed amino acid variation in the non-epitope region. The R values calculated among vaccine strain BEFV1984 (Tn73) and current epidemic stains by cross-neutralization tests presented 16.1% (BEFV1996), 6.3% (BEFV1999) and 5.3% (BEFV2001). The commercial vaccine strain BEFV1984 (Tn73) and recent isolates belonged to a single serotype, but could be further classified into distinct subtypes. However, the R value of BEFV1999 (Tn88128) and BEFV2001 was 70.7% greater than 70% present little or no antigenic difference. From the sequence data and the R value may indicate antigenic difference. Based on these observations, we chose Tn88128 strain (1999 isolate) for the preparation of a combined vaccine with Tn73 strain (1984 isolate). This combined vaccine provides a prolonged immunity, does not cause any adverse effects in cattle, and also complied with the criteria specified by the specificity, sterility, safety and efficacy tests [9] . The pathogencity of the challenge virus were shown to be insignificant since it have been passed through the BHK21 cells, not directly from BEFV-infected cow's blood. So it seems that the commercial vaccine was also effective to protect against the challenge of current epidemic BEF virus strain (Table 3) . Further study is needed to evaluate the efficacy of the combined vaccine to provide prolonged immunity against heterologous challenge.
The effectiveness immunity of a vaccine depends on the physical association between antigen and adjuvant [1] . Alu- minum salt is the only adjuvant for use in humans but is not effective in some vaccination trials. It has been reported that Quil A or Quil A combined with dextran sulphate may serve as better adjuvant than aluminum hydroxide gel for BEFV [20, 21] . Vaccination of recombinant glycoprotein G with Quil A has been reported to induce protection against challenge [19] . Commercially available Al-gel vaccine with Tn73 strain is administered 3-4 times per year because it provides poor immune response [17] . The w/o/w emulsions possess the advantages of both water and oil-based vaccines, with the outer aqueous antigens stimulating the immediate production of reactive antibodies. Therefore, the w/o/w vaccine serves not only as a suitable antigen delivery system but also stimulation of a prolonged immunity. The w/o/w vaccine elicited a better immune response in calves with a longer duration of immunity compared to an aluminum salts adjuvant in this study.
In conclusion, Tn73 and Tn88128 were selected for the development of a BEFV vaccine. Inactivated oil-based combined vaccine stimulated a high titer of neutralizing antibodies after vaccination. In addition, the w/o/w biphasic emulsion is low in viscosity, easy to inject by syringe and does not induce granulomas at the injection site. Our data indicate that BEF combined vaccine with oil adjuvant not only provides a protective immune response but also provide a prolonged immunity against BEFV infection. Fever, salivation and leucopenia a) Twenty 5-6-month-old calves were divided into 4 groups (5 per group). Group A vaccinated 3 ml of w/o/w vaccine, group B vaccinated 5 ml of Al-gel vaccine, group C vaccinated 3 ml of commercial Al-gel vaccine, group D used as the control. b) At 8 weeks, 2 calves randomly selected from each group were moved into the isolation building and challenged with 5 ml of (Tn88128) 10 5.5 TCID 50 /ml intravenously. 
